Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 10/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | UGCG | Q16739 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564393 | 0.93 | SCN5A (0.44) | AAK1SCN5ASCN9A | |
| SCHEMBL5558112 | 0.91 | AAK1 (0.42) | AAK1SCN5ASCN9AUGCG | |
| SCHEMBL5564343 | 0.90 | SCN9A (0.45) | AAK1SCN5ASCN9AUGCGPOLB | |
| SCHEMBL5557546 | 0.90 | ABL1 (0.42) | ABL1AAK1SCN5ASCN9AWNT3A | |
| SCHEMBL5557288 | 0.90 | ABL1 (0.42) | ABL1AAK1SCN5ASCN9AWNT3A | |
| SCHEMBL5557741 | 0.90 | CYP1A2 (0.41) | AAK1SCN5ASCN9AUGCG | |
| SCHEMBL5563562 | 0.89 | SCN5A (0.41) | AAK1SCN5ASCN9A | |
| SCHEMBL5557208 | 0.89 | ABL1 (0.42) | ABL1AAK1SCN5ASCN9AWNT3A | |
| SCHEMBL5558526 | 0.89 | ABL1 (0.42) | ABL1AAK1SCN5ASCN9AWNT3A | |
| SCHEMBL5556944 | 0.89 | AAK1 (0.43) | AAK1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | ABL1 1860/4885AAK1 2928/4885SCN5A 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.